Endocan is a key player in cardiovascular disease: A review
| Autor: | Amina M. Alieva, Elena V. Reznik, Irina E. Baykova, Natalia V. Teplova, Liudmila M. Makeeva, Kira V. Voronkova, Nyurzhanna Kh. Khadzhieva, Anna V. Modestova, Gaiane G. Totolyan, Ramiz K. Valiev, Alexander M. Li, Irina A. Kotikova, Igor G. Nikitin |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Consilium Medicum, Vol 25, Iss 1, Pp 20-28 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2075-1753 2542-2170 20751753 |
| DOI: | 10.26442/20751753.2023.1.202079 |
| Popis: | In recent years, the attention of scientists has been actively focused on studying the role of endocan as a biological marker of endothelial dysfunction in cardiovascular diseases. Until recent years, endocan has been studied in acute kidney injury, chronic kidney disease, and renal replacement therapy. Endocan, formerly known as endothelial cell-specific molecule-1, is a soluble dermatan sulfate proteoglycan expressed and secreted into the circulation from endothelial cells. Currently available studies demonstrate the diagnostic and prognostic value of endocan evaluation in cardiovascular pathology. It is expected that further scientific and clinical studies will demonstrate the possibilities of using endocan as an additional laboratory tool for diagnosing and assessing the prognosis in patients with a cardiac profile. Drug regulation of endocan concentration and expression may be a promising target for the treatment of cardiac and vascular pathology. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|